Advertisement

Topics

ImmusanT Inc. Company Profile

10:47 EST 19th December 2018 | BioPortfolio

ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow ImmusanT on Twitter.


News Articles [4 Associated News Articles listed on BioPortfolio]

ImmusanT receives JDRF T1D Fund to develop novel vaccine candidate for type 1 diabetes

ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ platform to translate and deliver first-in-class peptide-based immune therapies to people living with...

ImmusanT Expands Platform to Type 1 Diabetes with Investment from JDRF T1D Fund

ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based ...

World’s first vaccine against coeliac disease to be tested in Australia

US-based pharmaceutical company ImmusanT, after worldwide trials, is all set to start clinical trials of a new vaccine against coeliac disease at the Royal Melbourne Hospital Clinical Trials Centre in...

ImmusanT Announces First Patient Dosed in Phase 2 Trial of Therapeutic Vaccine for Celiac Disease

ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

ImmusanT Inc.

ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagn...

ImmusanT, Inc.

ImmusanT is a privately held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagn...

More Information about "ImmusanT Inc." on BioPortfolio

We have published hundreds of ImmusanT Inc. news stories on BioPortfolio along with dozens of ImmusanT Inc. Clinical Trials and PubMed Articles about ImmusanT Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmusanT Inc. Companies in our database. You can also find out about relevant ImmusanT Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


Corporate Database Quicklinks



Searches Linking to this Company Record